Oncolytics Biotech Inc. (ONCY)

NASDAQ: ONCY · IEX Real-Time Price · USD

1.025

+0.005 (0.49%)

Jul 22, 2024, 9:59 AM EDT - Market open

Oncolytics Biotech Employees

Oncolytics Biotech had 29 employees as of December 31, 2022. The number of employees increased by 3 or 11.54% compared to the previous year.

Employees

29

Change (1Y)

3

Growth (1Y)

11.54%

Revenue / Employee

n/a

Profits / Employee

-$972,724

Market Cap

77.37M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2022	29	3	11.54%
Dec 31, 2021	26	1	4.00%
Dec 31, 2020	25	-	-

Related Stocks

Company Name	Employees
SHL Telemedicine	583
MDxHealth	300
PetMed Express	287
Marinus Pharmaceuticals	166
Eagle Pharmaceuticals	134
T2 Biosystems	113
Affimed	76
Leap Therapeutics	54

Employee Rankings

ONCY News

25 days ago - Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program - PRNewsWire
4 weeks ago - Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence - PRNewsWire
4 weeks ago - Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer - PRNewsWire
2 months ago - Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action - PRNewsWire
2 months ago - Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders - PRNewsWire
2 months ago - Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial - PRNewsWire
2 months ago - Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights - PRNewsWire
2 months ago - Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer - PRNewsWire